

Table S1. Previous reports on re-irradiation of locoregional esophageal cancer.

Author, year	No	Re-irradiation interval, mo	Initial dose, Gy	Re-irradiation dose, Gy	Patients receiving concurrent chemotherapy (%)	Median follow-up, mo	Results	Toxicity (acute=within 3 mo)	(Refs.)
Katano <i>et al</i> , 2017	6	17.4	50.4	30-50.4; mean, 42.63	83.30	NR	MST 13.6 mo	Acute grade 1-2: 50% Acute grade 3-5: 50% Late grade 1-2: 50% Late grade 3-5: 16.6%	(7)
Kim <i>et al</i> , 2012	10	15.6	50.4	44-50.4; mean, 46.5	30	4.9	MST NR. At 3 mo: 20% CR, 10% PR, 20% SD, 50% PD	Acute grade 1-2: 90% Acute grade 3-5: 30%. Late grade 1-2: 10% Late grade 3-5: 0%	(3)
Yamashita <i>et al</i> , 2017	237	11.9	50-50.4	60	84	15 overall, 29.6 for 93 living patients	MST 21.6 mo	Acute grade 1-2: NR Acute grade 3-5: 2.9% Late grade 1-2: NR Late grade 3-5: 1.7%	(4)

No, number of patients; mo, month; NR, not reported; MST, median survival time; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.